U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Commission File
Number (1-10113)
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR
For Period Ended: March 31, 2003
--------------
[ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended:_______________________________________________
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification
relates:______________________________________________________________________
______________________________________________________________________________
PART I
REGISTRANT INFORMATION
Full Name of Registrant HALSEY DRUG CO., INC.
-----------------------------
Former Name if Applicable
Address of Principal Executive Office (Street and Number)
695 No. Perryville Road
_________________________________________
City, State and Zip Code
Rockford , Illinois 61107
_________________________________________
PART II
RULE 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report or semi-annual report, transition
report on Form 10-K, 11-K or Form N-SAR, or portion thereof will be
filed on or before the 15th calendar day following the prescribed due
date; or the subject quarterly report or transition report on Form
10-Q, or portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 11-K, 20-F,
10-Q, N-SAR or the transition report portion thereof could not be filed
within the prescribed time period.
On March 31, 2003, the Company applied for an extension of time to file its
Form 10-K for the year ended December 31, 2002. The Company completed and filed
its Form 10-K on May 9, 2003. The delay in the filing of the Form 10-K delayed
the availability of financial information required to complete and file Form
10-Q for the fiscal quarter ended March 31, 2003. The Management anticipates
the preparation and filing of Company's Form 10-Q for the fiscal quarter ended
March 31, 2003 on or before the 5th calendar day following its prescribed due
date.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification:
Peter Clemens, Chief Financial Officer (815) 399-2060
----------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the [X] Yes No [ ]
preceding 12 months or for such shorter period
that the registrant was required to file such
report(s) been filed? If the answer is no, please
identify report(s).
(3) Is it anticipated that any significant change
in results of operations from the corresponding [X] Yes No [ ]
period for the last fiscal year will be reflected
by the earnings statements to be included in the
subject report or portion thereof?
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
HALSEY DRUG CO., INC.
---------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: May 15, 2003 By: /s/ Peter Clemens
-----------------------------
Peter Clemens, Vice President
and Chief Financial Officer